The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1593
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
Download PDF:   US English
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
  • F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the mechanism behind a potential interaction between opioids and oral P2Y12 platelet inhibitors.
 Select a term to see related articles  Brilinta   cangrelor   Clopidogrel   Effient   Kengreal   Morphine   Opioids   Plavix   Prasugrel   ticagrelor 

Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y12 inhibitors clopidogrel (Plavix, and generics), prasugrel (Effient, and generics), and ticagrelor (Brilinta), which are commonly used for initial treatment of acute coronary syndrome (ACS). An article in our February 25, 2019 issue reviewed studies showing that coadministration of opioids delayed and decreased absorption of oral P2Y12 inhibitors and increased platelet reactivity.1 Recently published clinical outcomes data may add to these concerns.

In a post-hoc subgroup analysis of the EARLY ACS trial, the effects of morphine were evaluated in 5,438 patients with non-ST-elevation ACS (NSTEACS) treated with clopidogrel and in 3,462 NSTEACS patients not treated with a P2Y12 inhibitor. In the clopidogrel group, the primary composite endpoint of death, myocardial infarction, recurrent ischemia, or thrombotic bailout at 96 hours occurred significantly more often in patients who received morphine than in those who did not (adjusted odds ratio 1.40; 95% CI 1.04-1.87). Morphine use was not associated with an increased incidence of adverse cardiovascular events in patients who did not receive a P2Y12 inhibitor.2

Although this was only a post-hoc analysis and not a randomized controlled trial of morphine use in clopidogrel-treated patients, it does provide some additional evidence that caution should be used with coadministration of oral P2Y12 inhibitors and opioids, and that use of the IV P2Y12 inhibitor cangrelor (Kengreal)3 should be considered in patients with ACS who require or are already taking an opioid agonist.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
arrow to previous article
arrow to next article